Abstract:Critical sized cartilage defects heal poorly and MSC-based therapies holds promise functional cartilage regeneration either used alone or in combination with growth factors. However, Recombinant protein growth factors were proven to have minimal benefits while to have adverse side effects and high cost. Nonviral mRNA delivery provides a promising, alternative approach to delivering therapeutic proteins within defect lesion for an extended period of time. Despite successful therapeutic outcome in bone and other vascularized tissues, the therapeutic application of mRNA in poorly vascularized tissues such as cartilage is still facing many challenges and rarely studied. We report here using chemically modified messenger RNA encoding TGF-β3(TGF-β3 cmRNA) to enhance the therapeutic efficacy of BMSCs to efficient repair of cartilage defect. Local administration of TGF-β3 cmRNA enhanced BMSCs therapy restored critical-sized cartilage defects in situ in a rat model within 6 weeks with structural and molecular markers similar to its nature counterparts. In addition, the development of osteoarthritis caused by cartilage damage was prevented by this mRNA-enhanced BMSCs therapy evidenced by minimal late-stage OA pharmacological presentations. This novel mRNA enhanced-MSC technology extend the development of new therapeutic approaches for treating functional cartilage repair. ### Competing Interest Statement YY received the research funding from:National Nature Science Foundation of China (82002355), Shenzhen Institute of Synthetic Biology Scientific Research Program (Grant No. DWKF20190010, JCHZ20200005), FC received the research funding from: the Shenzhen Institutes of Advanced Technology Innovation Program for Excellent Young Researchers (Y9G075), GeneHeal Medicine-SIAT mRNA Regenerative Medicine Laboratory (E1Z124) . LZ received the research funding from: the National Natural Science Foundation of China [81660364, 81760343], Jiangxi Provincial Department of Education Research Program Major Project (171352), Science and Technology Planning Project of Jiangxi Health Commission (20191025, 202130131). XZ received the research funding National Nature Science Foundation of China (32071341). GW, JH, FY are employee at Gene Heal Medicine, a privately owned company developing mRNA therapeutics.All others have no potential conflict of interest.

MSX1 + PDGFRA low limb mesenchyme-like cells as an efficient stem cell source for human cartilage regeneration

Molecular and Cellular Characterization During Chondrogenic Differentiation of Adipose Tissue-Derived Stromal Cells in Vitro and Cartilage Formation in Vivo

Cartilage Repair Using Hyaluronan Hydrogel-Encapsulated Human Embryonic Stem Cell-Derived Chondrogenic Cells

Mesenchymal stem cell-based treatment for cartilage defects in osteoarthritis

Cartilage Regeneration Using Arthroscopic Flushing Fluid-Derived Mesenchymal Stem Cells Encapsulated in a One-Step Rapid Cross-Linked Hydrogel

Osteochondral repair using porous poly(lactide-co-glycolide)/nano-hydroxyapatite hybrid scaffolds with undifferentiated mesenchymal stem cells in a rat model.

Highly efficient healing of critical sized articular cartilage defect in situ using a chemically nucleoside-modified mRNA-enhanced cell therapy

Repair of injured articular and growth plate cartilage using mesenchymal stem cells and chondrogenic gene therapy

Human Cartilage-Derived Progenitor Cells from Committed Chondrocytes for Efficient Cartilage Repair and Regeneration

Synergistic effects on mesenchymal stem cell-based cartilage regeneration by chondrogenic preconditioning and mechanical stimulation

Promotion of osteochondral repair through immune microenvironment regulation and activation of endogenous chondrogenesis via the release of apoptotic vesicles from donor MSCs

Matrix from urine stem cells boosts tissue-specific stem cell mediated functional cartilage reconstruction

Genetically Modified Mesenchymal Stromal Cells in Cartilage Regeneration

Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells And Bmp7 Promote Cartilage Repair

Allogeneic mesenchymal stromal cells for cartilage regeneration: A review of in vitro evaluation, clinical experience, and translational opportunities

Human Mesenchymal Stromal Cells Enhance Cartilage Healing in a Murine Joint Surface Injury Model

Mesenchymal stem cells for cartilage regeneration: Insights into molecular mechanism and therapeutic strategies

A Functional Biphasic Biomaterial Homing Mesenchymal Stem Cells for in Vivo Cartilage Regeneration

Mesenchymal Stem Cell Engineering

Intra-articular injection of human meniscus stem/progenitor cells promotes meniscus regeneration and ameliorates osteoarthritis through stromal cell-derived factor-1/CXCR4-mediated homing.

Efficiently directing differentiation and homing of mesenchymal stem cells to boost cartilage repair in osteoarthritis via a nanoparticle and peptide dual-engineering strategy